Linked Life Data

12398964

Source:http://linkedlifedata.com/resource/pubmed/id/12398964

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2002-10-25
pubmed:abstractText
The myocardial contractile protein myosin light chain 1 isoform (MLC-1) is released into the circulation during myocyte necrosis and could thus be a marker of low-grade myocardial damage and of poor prognosis in patients with heart failure. Two hundred eighteen patients with stable heart failure (ejection fraction [EF] <35%) and in New York Heart Association (NYHA) class III to IV had MLC-1 measured at baseline and 1 month after being randomized to the direct vasodilator flosequinan or placebo. Patients were followed a mean of 302 +/- 142 days. The prognostic value of an increase in MLC-1 above the 98th percentile of normal controls was compared with that of conventional prognostic variables in heart failure. MLC-1 was increased in over half of patients at baseline and 1 month, and this was associated with increased age, NYHA class IV, and renal insufficiency. By Kaplan-Meier survival analysis, patients with a baseline increase in MLC-1 had a greater mortality (26%) than those without an increase (15%) (p = 0.043). A significant interaction among MLC-1, survival, and treatment was found (p = 0.043). In the placebo group, MLC-1 was associated with increased mortality (29% vs 12%, p = 0.025), whereas there was no significant difference among patients receiving flosequinan. In a multivariate logistic regression model including age, treatment, and left ventricular (LV) ejection fraction, the MLC-1 chain was most predictive of mortality (p = 0.049). Thus, circulating MLC-1 is elevated in over half of patients with stable severe heart failure, and this increase is associated with a poor prognosis. Flosequinan treatment eliminates this association, highlighting the complexity of the relation between cardiac myocyte damage, drug treatment, and mortality.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
969-73
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:12398964-Adolescent, pubmed-meshheading:12398964-Adult, pubmed-meshheading:12398964-Aged, pubmed-meshheading:12398964-Aged, 80 and over, pubmed-meshheading:12398964-Biological Markers, pubmed-meshheading:12398964-Double-Blind Method, pubmed-meshheading:12398964-Female, pubmed-meshheading:12398964-Follow-Up Studies, pubmed-meshheading:12398964-Heart Failure, pubmed-meshheading:12398964-Humans, pubmed-meshheading:12398964-Male, pubmed-meshheading:12398964-Middle Aged, pubmed-meshheading:12398964-Multivariate Analysis, pubmed-meshheading:12398964-Myosin Light Chains, pubmed-meshheading:12398964-North America, pubmed-meshheading:12398964-Predictive Value of Tests, pubmed-meshheading:12398964-Prospective Studies, pubmed-meshheading:12398964-Quinolines, pubmed-meshheading:12398964-Scandinavia, pubmed-meshheading:12398964-Severity of Illness Index, pubmed-meshheading:12398964-Stroke Volume, pubmed-meshheading:12398964-Survival Analysis, pubmed-meshheading:12398964-Treatment Outcome, pubmed-meshheading:12398964-Vasodilator Agents
pubmed:year
2002
pubmed:articleTitle
Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
pubmed:affiliation
Division of Cardiology of the University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Evaluation Studies